ホーム / ニュース / Certara to Host Inaugural Symposium Dedicated to Advancing Pediatric Drug Development

Certara to Host Inaugural Symposium Dedicated to Advancing Pediatric Drug Development

Princeton, N.J., 2021 年 8 月 4 日: Certara, the global leader in biosimulation, today announced it will host the inaugural New Horizons in Pediatric Drug Development Symposium taking place October 28-29, 2021. The two-day virtual symposium is being held to bring together thought leaders and innovators in pediatric drug development to share new developments in the field and to collaborate on new ideas to advance pediatric drug development into a new era.
“We are thrilled to have such an amazing group of speakers and renowned experts to support the advancement of drug development in pediatrics,” said Patrick Smith, PharmD., Senior Vice President of Integrated Drug Development at Certara and chair of the organizing committee. “Pediatric drug development is rapidly evolving, with exciting new tools and emerging technologies, which address some of the inherent complexities associated with developing drugs for children. We look forward to the exciting conversations this event will bring forth.”
The symposium is spearheaded by an organizing committee comprised of regulatory and drug development experts in the biopharmaceutical industry. Keynote speaker, Lynne Yao, M.D., Director at the FDA Division of Pediatric and Maternal Health, Center for Drug Evaluation and Research, will discuss challenges and opportunities to accelerate global pediatric drug development. Additionally, the agenda features speakers who will speak about the regulatory environment, clinical trial innovation, and the changing landscape with the recent passing of the US FDA’s Research to Accelerate Cures and Equity for Children Act to expand and encourage pediatric drug development, specifically in oncology.
“Being passionate about paediatric development, I am very proud and honoured to be part of this symposium. This is the opportunity to bring together distinguished experts to share their views and experience, which will certainly benefit all involved,” said Solange Corriol-Rohou, M.D., Senior Global Regulatory Policy Director at AstraZeneca. “It is amazing to see how paediatric development has evolved and been optimised these last few years. Multi-stakeholder collaboration has increased with the uptake of new tools and methods, such as digital technologies, extrapolation or quantitative approaches, for the benefit of children in need.”
To register for the virtual symposium please visit https://www.newhorizonpdd.org/.


Certara(サターラ) について

サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。

投資家の皆様:

David Deuchler
Gilmartin Group
ir@certara.com

※英語または日本語でお問合せください

衣斐桃果 m-ebi@prap.co.jp
Finn Partners
ariane.lovell@finnpartners.com 

※英語または日本語でお問合せください

トップに戻る
Powered by Translations.com GlobalLink OneLink Software